Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized Cancer Therapy Considering Cytochrome P450 Variability.

Advances in pharmacology (San Diego, Calif.) - 1 Jan 2015

Preissner Saskia, Simmaco Maurizio, Gentile Giovanna, Preissner Robert

Abstract excerpt

The individual variability of pharmacokinetics is underestimated and few systematic studies exist in this field. In most cases, this leads to unwanted side effects or toxicity. In polychemotherapy, prodrugs (like ifosfamide), which have to be activated by cytochrome P450 enzymes (CYPs), play an important role. If patients are poor metabolizers for these drugs, the therapy will be ineffective. Furthermore, CYPs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 Enzyme System
Share to Genotype
Share to Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to Precision Medicine

Share to Prodrugs

Source

Identifiers

PMID: 26233905
DOI: 10.1016/bs.apha.2015.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized Cancer Therapy Considering Cytochrome P450 Variability.PMID 26233905Read ↗

Contributing factors on metabolic mechanism-based CYP3A4-activated/deactivated anticancer drugs: implications for individualizing chemotherapySemantic proximity Read ↗

Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.Semantic proximity Read ↗

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read ↗

Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.Semantic proximity Read ↗

[Anticancer drug dosing--pharmacogenomic biomarkers or body surface area?].Semantic proximity Read ↗

Molecular modeling of cytochrome P450 and drug metabolism.Semantic proximity Read ↗

Cytochrome P450 in Cancer Susceptibility and Treatment.Semantic proximity Read ↗

Cytochrome P450: Implications for human breast cancer (Review)Semantic proximity Read ↗

Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment.Semantic proximity Read ↗

Cytochrome P450 gene polymorphism and cancer.Semantic proximity Read ↗

Pharmacogenomics of Cytochrome P450 Enzymes in Tumours.Semantic proximity Read ↗

Interethnic differences of cytochrome P450 gene polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.